Abstract
Purpose: To determine the feasibility of a case-control study of phosphodiesterase (PDE)-5 inhibitors and nonarteritic ischemic optic neuropathy (NION). Design: Retrospective cohort study using the National Veterans Health Administration's pharmacy and clinical databases. Methods: setting: National database. patient population: Male veterans 50 years of age and older with newly diagnosed NION or "possible" NION. interventional procedure: Dispensed prescription for a PDE-5 inhibitor. outcome measure: Incidence of NION and "possible" NION based on exposure to PDE-5 inhibitors. Results: The relative risk of NION among men prescribed a PDE-5 inhibitor was 1.02 (95% confidence interval [CI]: 0.92 to 1.12). The relative risk of possible NION among men prescribed a PDE-5 inhibitor was 1.34 (95% CI: 1.17 to 1.55). Conclusions: The collective risk of NION and possible NION was marginally significant (relative risk [RR] 1.10 95% CI: 1.02 to 1.20). A case-control study, in which the dependent variable is NION and the effect size of the PDE-5 inhibitor is assumed small, is feasible.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 538-539 |
| Number of pages | 2 |
| Journal | American journal of ophthalmology |
| Volume | 143 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2007 |
Funding
This study was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA), Tampa, Florida. The authors indicate no financial conflict of interest. Both authors were involved in the design and conduct of study; collection, management, analysis and interpretation of data, and preparation of the data; collection of data; and management, statistical analysis and interpretation of the data, and preparation of the manuscript.
ASJC Scopus subject areas
- Ophthalmology